We are live on ! Find out more
EC

EcoR1 Capital Portfolio holdings

AUM $2.06B
1-Year Est. Return 215.32%
This Fund
S&P 500
This Quarter Est. Return
+37.44%
1 Year Est. Return
+215.32%
3 Year Est. Return
+310.3%
5 Year Est. Return
+497.45%
10 Year Est. Return
+14,692.23%
AUM
$2.2B
AUM Growth
+$120M
Cap. Flow
-$379M
Cap. Flow %
-17.19%
Top 10 Hldgs %
84.63%
Holding
41
New
11
Increased
2
Reduced
3
Closed
11

Top Buys

Rank Stock Value
1
CNTA
Centessa Pharmaceuticals
CNTA
+$65M
2
CGON icon
CG Oncology
CGON
+$31.9M
3
ZBIO
Zenas BioPharma
ZBIO
+$26M
4
PCVX icon
Vaxcyte
PCVX
+$20.1M
5
MREO
Mereo BioPharma
MREO
+$15M

Top Sells

Rank Stock Value
1
QURE icon
uniQure
QURE
+$233M
2
TNGX icon
Tango Therapeutics
TNGX
+$89.3M
3
APLS
Apellis Pharmaceuticals
APLS
+$78M
4
XNCR icon
Xencor
XNCR
+$43.2M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$34.4M

Sector Composition

Rank Sector Weight
1 Healthcare 99.01%
2 Miscellaneous 0.99%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
1
Zymeworks
ZYME
$2.02B
$605M 27.44%
22,970,388
– –
ANAB icon
2
AnaptysBio
ANAB
$1.67B
$382M 17.33%
7,880,094
– –
JAZZ icon
3
Jazz Pharmaceuticals
JAZZ
$15.9B
$290M 13.16%
1,706,469
– –
CRNX icon
4
Crinetics Pharmaceuticals
CRNX
$9B
$200M 9.06%
4,288,120
– –
CNTA
5
DELISTED
Centessa Pharmaceuticals
CNTA
$77.9M 3.53%
3,115,000
+2,565,000
+466% +$65M
CRSP icon
6
CRISPR Therapeutics
CRSP
$5.58B
$72.9M 3.31%
1,389,276
– –
MBX
7
MBX Biosciences
MBX
$3.03B
$67M 3.04%
2,123,604
– –
IMNM icon
8
Immunome
IMNM
$3.13B
$61.3M 2.78%
2,855,590
-1,223,825
-30% -$21.5M
ORIC icon
9
Oric Pharmaceuticals
ORIC
$1.37B
$55M 2.5%
6,728,116
– –
LKFT
10
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$54.5M 2.47%
1,667,119
– –
XNCR icon
11
Xencor
XNCR
$1.94B
$49.8M 2.26%
3,251,112
-2,893,655
-47% -$43.2M
BBOT
12
BridgeBio Oncology
BBOT
$701M
$35.3M 1.6%
2,823,126
– –
ETON icon
13
Eton Pharmaceutcials
ETON
$1.71B
$34.3M 1.56%
2,030,544
– –
CGON icon
14
CG Oncology
CGON
$6.59B
$32.1M 1.45%
+772,000
New +$31.9M
ZBIO
15
Zenas BioPharma
ZBIO
$2.04B
$28.7M 1.3%
+789,500
New +$26M
NGNE icon
16
Neurogene
NGNE
$732M
$26.2M 1.19%
1,271,342
– –
GPCR icon
17
Structure Therapeutics
GPCR
$3.38B
$23.3M 1.06%
+334,380
New +$13.7M
PCVX icon
18
Vaxcyte
PCVX
$8.9B
$20.8M 0.94%
+450,000
New +$20.1M
AQST icon
19
Aquestive Therapeutics
AQST
$630M
$17M 0.77%
2,625,000
– –
VYGR icon
20
Voyager Therapeutics
VYGR
$218M
$15.7M 0.71%
4,002,847
+3,332,544
+497% +$14.7M
CGON icon
21
CALL
CG Oncology
CGON
$6.59B
$12.2M 0.55%
+292,800
New +$12.1M
ATRA icon
22
Atara Biotherapeutics
ATRA
$92.3M
$10.4M 0.47%
573,183
– –
MNKD icon
23
MannKind Corp
MNKD
$1.27B
$9.41M 0.43%
+1,660,000
New +$9.14M
NUVB.WS
24
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$8.63M 0.39%
963,333
– –
EOLS icon
25
Evolus
EOLS
$587M
$4.49M 0.2%
+675,000
New +$4.57M
1
2

Similar funds

RHJA
Rice Hall James & Associates San Diego, California $2.05B AUM 43.16% 1-Year Est. Return
ST
Spinnaker Trust Portland, Maine $2.06B AUM 24.94% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return

EcoR1 Capital's Q4 2025 Portfolio in Review

As of Q4 2025, EcoR1 Capital held 41 positions worth $2.2B, up 5.8% from $2.08B the previous quarter. Its ten largest holdings account for 85% of the portfolio.

EcoR1 Capital withdrew a net $379M in Q4 2025, closing 11 positions and reducing 3 holdings. Its most notable exit was uniQure, an estimated $233M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, EcoR1 Capital opened a new position in CG Oncology worth $32.1M.

  • EcoR1 Capital's largest Q4 2025 buy was CG Oncology: 772,000 shares worth $32.1M.
  • EcoR1 Capital added most to Centessa Pharmaceuticals in Q4 2025, an estimated $65M increase.
  • EcoR1 Capital's biggest Q4 2025 reduction was Xencor, cutting an estimated $43.2M.
  • EcoR1 Capital fully exited uniQure in Q4 2025, selling an estimated $233M.
  • EcoR1 Capital's ten largest holdings make up 85% of its $2.2B portfolio in Q4 2025.
  • EcoR1 Capital opened 11 new positions and closed 11 in Q4 2025.
  • EcoR1 Capital's portfolio value rose 5.8% quarter-over-quarter to $2.2B.

Based on EcoR1 Capital's 13F filing for Q4 2025, filed 17 Feb 2026.